Healthcare ❯ Pharmaceuticals

Obesity Treatments

Drug Development GLP-1 Drugs Wegovy Market Competition GLP-1 Medications Clinical Trials Weight Loss Drugs Diabetes Treatments Next-Generation Drugs Weight Loss Medicines Weight Loss Medications Manufacturing Market Dynamics Biotech Companies Medications Oral Therapies Patient Affordability Eli Lilly

Lilly Says Foundayo Now Drives One-Third of New Oral GLP-1 Starts as It Breaks Ground on $6.5 Billion Houston Plant

The project seeks to lock in U.S. supply for Foundayo to meet surging demand from Medicare coverage plus planned international rollouts.

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Analysts Lift Eli Lilly Price Targets as Medicare Expands Low‑Cost GLP‑1 Access

UK Clears Oral Wegovy and Foundation Pledges Europe Research Cash

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

HSBC Cuts Eli Lilly to Reduce, Lowers Target to $850 on GLP-1 Reset

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength

Lilly's Rally Deepens as U.S. Access Deal Recasts Outlook for GLP‑1 Drugs

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws